News and Updates

Medical Affairs (+Research and Advocacy) Breakthrough T1D’s Medical Affairs program is bridging the gap between access to and adoption of therapies, treatments, drugs, and devices for T1D. To accomplish this goal, the Medical Affairs team is working on healthcare provider (HCP) education, development of clinical care guidelines, and clinical trial education and awareness. Breakthrough T1D’s […]

Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type 1 diabetes.

Improving Lives Breakthrough T1D’s Improving Lives program focuses on devices, insulins, adjunctive therapies, treatments for complications, and psychosocial interventions to improve the health and quality of life of people living with T1D. Adjunctive therapies and complications There was significant focus on GLP-1 receptor agonists (GLP-1RAs) and SGLT inhibitors (SGLTi) in reducing long-term complications and improving […]

Breakthrough T1D is heading to Chicago, IL to attend the 2025 ADA conference from June 20-23 to discuss cutting-edge type 1 diabetes updates.

This meeting focused on the role of the EU in addressing the needs of the T1D community and accelerating T1D breakthroughs.

Breakthrough T1D's Medical Affairs team hosted experts in islet transplantation to discuss a clinical roadmap for manufactured cell therapies.

Breakthrough T1D recently published two peer-reviewed journal articles. One detailed burdensome unmet needs in the T1D community and identified key steps we can take to meet these needs. The other used real-world data to better understand American T1D demographics and predict changes in the next decade.

Matt Varey, a key volunteer with Breakthrough T1D, will embark on a two-month-long, 7,500 km cycling journey across Canada to fundraise for the type 1 diabetes community.

Katie Howell was diagnosed with type 1 diabetes last year at age 25. Now, she's the first DIAGNODE-3 trial participant in NYC.

At ATTD 2025, Breakthrough T1D led sessions showcasing advancements in T1D cell therapies, early detection, and technology to improve lives.